CIPLA Cipla Q3 FY25 results (Oct–Dec 2024) and concall
Cipla reported its highest-ever quarterly revenue of ₹7,073 crores, up 8% YoY, and an all-time high EBITDA margin of 28% for Q3 FY25. Growth was robust across India, North America, Africa, and EMEU, with strong traction in branded prescriptions and Albuterol market share. However, launch delays for key US assets like Abraxane and ongoing supply issues for Lanreotide were noted. Management clarified that the Q3 margin is not sustainable for future quarters and provided updated FY25 guidance for EBITDA and ETR.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 |
|---|---|
| Revenue | 4,971 |
| EBITDA | 1,662 |
| Net profit | 1,438 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
